Wells Fargo lowered the firm’s price target on Acelyrin (SLRN) to $13 from $15 and keeps an Overweight rating on the shares. The firm notes izo’s Phase 2b/3 trial in uveitis failed; downside should be limited since there was no value assigned anyway. Wells is removing its izo uveitis contribution from its model as it will not be developed any further.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue